Abstracts Archive - Page 2432 of 2607 - ACR Meeting Abstracts

Abstract Number: 2604 • 2012 ACR/ARHP Annual Meeting
Ask a Doc – Rheumatologic Care Delivered Just in Time
Eric D. Newman¹, Chelsea Cedeno², Thomas M. Harrington³, Thomas P. Olenginski³, Alfred E. Denio³, Androniki Bili⁴, Brian DelVecchio⁵, Carolyn Houk⁶ and Paul F. Simonelli⁷, ¹Department of Rheumatology, Geisinger Health System, Danville, PA, ²Division of Medicine, Geisinger Medical Center, Geisinger Health System, Danville, PA, ³Dept of Rheumatology, Geisinger Health System, Danville, PA, ⁴Rheumatology, Geisinger Medical Center, Danville, PA, ⁵Rheumatology, Geisinger Health System, Wilkes-Barre, PA, ⁶Family Practice - Frackville, Geisinger Health System, Frackville, PA, ⁷Thoracic Medicine, Geisinger Medical Center, Danville, PA
Background/Purpose: Specialty care is traditionally delivered as face to face consults. These encounters range from consult not needed to consult needed quickly. Our care systems…
Abstract Number: 2605 • 2012 ACR/ARHP Annual Meeting
Exploration of Possible Preliminary Descriptions of Remission Based On RAPID3, without Laboratory Tests or Formal Joints Counts but with Careful Joint Examinations, in the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort of Early Rheumatoid Arthritis Patients
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Bruno Fautrel⁴ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: Criteria for remission in rheumatoid arthritis (RA) have been developed according to DAS28 (disease activity score), CDAI (clinical disease activity index), and two recent…
Abstract Number: 2566 • 2012 ACR/ARHP Annual Meeting
Aβ-Related Angiitis: Comparison with Patients with Amyloid Cerebral Angiopathy without Inflammation
Carlo Salvarani¹, Caterina Giannini², Robert D. Brown Jr.², Teresa J. H. Christianson² and Gene G. Hunder³, ¹Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ²Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Coexistence of sporadic cerebral amyloid angiopathy (CAA) and primary central nervous system vasculitis (PCNSV) has been reported, particularly in patients with granulomatous vasculitis. This…
Abstract Number: 2567 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Selected Markers of Inflammation and Platelet Activation for Complete Remission in ANCA – Associated Vasculitis
Gunnar Tomasson¹, Paul A. Monach², Kahraman Tanriverdi³, Ulrich Specks⁴, John H. Stone⁵, Linna Ding⁶, Fernando Fervenza⁴, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, Carol A. Langford⁹, Deborah J. Phippard¹⁰, Philip Seo¹¹, Robert F. Spiera¹², E. William St. Clair¹³, Nadia Tchao¹⁰, Jane E. Freedman³ and Peter A. Merkel¹⁴, ¹Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland, ²Rheumatology, Boston University, Boston, MA, ³Department of Cardiology, University of Massachusetts, Wochester, MA, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatology, Massachusetts General Hospital, Boston, MA, ⁶NIAID, Bethesda, MD, ⁷Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Medicine, Duke University Medical Center, Durham, NC, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Most subjects with ANCA –associated vasculitis (AAV) respond to treatment for remission induction, but predictors for complete disease remission are lacking. We have previously…
Abstract Number: 2568 • 2012 ACR/ARHP Annual Meeting
The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Giant Cell Arteritis: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Diane Lacaille², Eric C. Sayre³, Jacek A. Kopec³ and Hyon Choi⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Arthritis Research Centre of Canada/University of British Columbia, Boston, MA
Background/Purpose: A recent hospital-based study has suggested an 8 fold increased risk of pulmonary embolism (PE) in individuals with polymyalgia rheumatica in the year following…
Abstract Number: 2569 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients
Genevieve Law¹, Laurence S. Magder², Hong Fang³ and Michelle Petri³, ¹Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Past studies, mostly cross-sectional, have found a reduction in thrombosis in systemic lupus erythematosus (SLE) patients taking hydroxychloroquine (HCQ). We examined the relationship between…
Abstract Number: 2570 • 2012 ACR/ARHP Annual Meeting
Lymphoma Risk in Systemic Lupus: Effects of Disease Activity Versus Treatment
Sasha Bernatsky¹, Ann E. Clarke², Karen H. Costenbader³, Murray B. Urowitz⁴, Dafna D. Gladman⁵, Paul R. Fortin⁶, Michelle Petri⁷, Susan Manzi⁸, D.A. Isenberg⁹, Anisur Rahman¹⁰, Daniel Wallace¹¹, Caroline Gordon¹², Christine Peschken¹³, Mary Anne Dooley¹⁴, E.M. Ginzler¹⁵, Cynthia Aranow¹⁶, Steven M. Edworthy¹⁷, Ola Nived¹⁸, Søren Jacobsen¹⁹, Guillermo Ruiz-Irastorza²⁰, Edward H. Yelin²¹, Susan G. Barr²², Irene Blanco²³, Candace H. Feldman²⁴ and R. Ramsey-Goldman²⁵, ¹Clinical Epidemiology, Systemic Lupus International Collaborating Clinics, Montreal, QC, Canada, ²Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto,, Toronto, ON, Canada, ⁵Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶University of Laval, Quebec, QC, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁰Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹¹Cedars-Sinai/UCLA, Los Angeles, CA, ¹²School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹³Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁵Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹⁶Feinstein Institute for Medical Research, Manhasset, NY, ¹⁷The University of Calgary, Calgary, AB, Canada, ¹⁸Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden, ¹⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²⁰Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ²¹Medicine, UC San Francisco, San Francisco, CA, ²²University of Calgary, University of Calgary, Calgary, AB, Canada, ²³Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²⁵Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: In systemic lupus (SLE), concern exists about immunosuppressive drugs and lymphoma risk, Yet, the relative influence of disease activity vs treatment, is unknown. Our objective…
Abstract Number: 2571 • 2012 ACR/ARHP Annual Meeting
Lack of Control of Hypertension in Systemic Lupus Erythematosus
Hong Fang¹, Raheel Ahmad², Laurence S. Magder³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Hypertension is an independent risk factor for both actual cardiovascular events and also subclinical atherosclerosis (coronary calcium, carotid IMT) in SLE. We examined the…
Abstract Number: 2572 • 2012 ACR/ARHP Annual Meeting
Molecular Signatures in SLE: Flare Vs. Infection
Meggan Mackay¹, Michaela Oswald², Jorge Sanchez-Guerrero³, Juan J. Lichuaco⁴, Cynthia Aranow⁵, Sean Kotkin⁶, Peter K. Gregersen⁷ and Betty Diamond⁸, ¹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ²Laboratory of Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, ³UHN Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, St. Luke's Medical Center, Quezon City, Philippines, ⁵Feinstein Institute for Medical Research, Manhasset, NY, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, ⁸Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY
Background/Purpose: Inability to distinguish between infection and the inflammatory response related to SLE disease activity using clinical judgment often compromises timely and effective treatment. Gene…
Abstract Number: 2573 • 2012 ACR/ARHP Annual Meeting
Arthoplasty Rates Increased Among US Patients with Systemic Lupus Erythematosus: 1991-2005
Christina Mertelsmann-Voss¹, Ting Jung Pan², Huong Do², Mark P. Figgie³ and Lisa A. Mandl⁴, ¹Pediatric Rheumatology, Hospital for Special Surgery, Cornell University, New York, NY, ²Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Orthopedics, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: There is little data regarding patterns of arthroplasty use in patients with Systemic Lupus Erythematosus (SLE). This study evaluates trends in total joint replacement…
Abstract Number: 2574 • 2012 ACR/ARHP Annual Meeting
Smoking, Autoantibodies and Vascular Events in Systemic Lupus Erythematosus
Johanna Gustafsson¹, Iva Gunnarsson¹, Susanne Pettersson¹, Agneta Zickert¹, Anna Vikerfors², Erik Hellbacher², Sonia Möller¹, Kerstin Elvin³, Henrik Källberg⁴, Julia F. Simard⁵ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Immunology and Transfusion Medicine,, Karolinska Institutet, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Smoking is a risk factor for several autoimmune diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Smoking is also a major risk…
Abstract Number: 2575 • 2012 ACR/ARHP Annual Meeting
Inhibition of Pathogenic Autoantibodies by Accelerating the Exit of Germinal Center B Cells Via Manipulation of Regulator of G-Protein Signaling
John D. Mountz¹, John H. Wang², James S. New³, PingAr Yang⁴, Qi Wu⁴, Bao Luo⁵, Jun Li⁶, Kirk M. Druey⁷ and Hui-Chen Hsu⁴, ¹Dept of Med/Rheumatology Div, Univ of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ²Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, ³Grad Sch - Biomed Sciences, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD
Background/Purpose: Regulator of G-protein Signaling (RGS) plays a key role in inhibiting chemokine signaling by desensitizing G-protein coupled receptor signals. RGS13 and RGS16 are two…
Abstract Number: 2576 • 2012 ACR/ARHP Annual Meeting
Production of Citrullinated Filaggrin-Specific IgG in Rheumatoid Arthritis Patients Is Associated with an Expansion of Citrullinated Filaggrin Tetramer-Binding Switched Memory Blood B Cells
Philip Titcombe¹, Laura O. Barsness¹, Lauren Giacobbe¹, Emily Baechler Gillespie¹, Erik J. Peterson² and Daniel L. Mueller², ¹University of Minnesota Medical School, Minneapolis, MN, ²Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN
Background/Purpose: Rheumatoid Arthritis (RA) is highly associated with the production of autoantibodies, including rheumatoid factors and anti-citrullinated protein antibodies (ACPA). It remains uncertain whether production…
Abstract Number: 2577 • 2012 ACR/ARHP Annual Meeting
Characterization of Circulating Human B Cells That Bind Cyclic Citrullinated Peptide Antigens in Clinically Active Rheumatoid Arthritis
Gregg J. Silverman¹, John Jung², Jeffrey D. Greenberg³, Adam J. Pelzek⁴, Caroline Gronwall⁵ and Jaya Vas⁵, ¹Medical and Pathology, NYU School of Medicine, New York, NY, ²School of Medicine, NYU, New York, NY, ³New York Hospital for Joint Disease, New York, NY, ⁴School of Medicine, NYU School of Medicine, New York, NY, ⁵Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) were first identified based on their high specificity for RA and now are commonly used as a diagnostic tool. Yet,…
Abstract Number: 2578 • 2012 ACR/ARHP Annual Meeting
Monoclonal IgG Antibodies (ACPAs) From Synovial Fluid B Cells of Rheumatoid Arthritis Patients – Antigen-Driven Affinity Maturation and Cross Reactivity
Khaled Amara¹, Johanna Steen², Fiona Murray², Henner Morbach³, Blanca Fernandez-Rodriguez⁴, Vijay Balasingh², Marianne Engström², Omri Snir², Lena Israelsson⁵, Anca Catrina², Hedda Wardemann⁶, Davide Corti⁴, Eric Meffre Sr.³, Lars Klareskog⁷ and Vivianne Malmström⁸, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, ²Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Department of Immunobiology, Yale University School of Medicine, New Haven, CT, ⁴Institute for Research in Biomedicine, Bellinzona, Switzerland, ⁵Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁶Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are commonly found in patients with Rheumatoid Arthritis (RA), strongly associate with distinct HLA-DR alleles and predict a more…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].